热门城市
2020，风浪迭起，新常态不断涌现：“募资难”的状况继续, 疫情成为长期影响, 全球市场的不确定性和复杂性加强，出海一言难尽……而对于创业者们而言，勇敢冲浪本就是工作的一部分。环境的变化不会影响努力前进的初心，只是需要更多的学习和调整。
2020 has been a whirlwind due to the COVID-19 pandemic and we are now entering a new normal. The current and future ramifications of the pandemic are accelerating changes in the business world and funding is even more challenging now. How do companies rebound and prosper in the post-pandemic world? How do we adjust and pivot in these challenging times?
关键成果 key takeaways
- 创业者分享他们行业最新趋势和工作方式
- 投资人会深度讨论各自对行业的见解以及对当下热点事件及投资规划的解读
- 互动性以及Q&A环节，能够让你直接提问嘉宾他们的投资经验及建议
- 通过创新性的云展位更是让你可以与目标嘉宾开展更多的沟通与互动，创造更多商业合作的可能性，提供比线下对接更好的体验。
1.Founders of companies will share the latest trends and their practices across technologies and verticals for the next norm.
2.Investors will share their industry insights and give their advice on funding planning.
3.An interactive and Q&A session where you can ask guest speakers about their funding experiences and advice.
4 As each company is provided with a cloud booth, you can also visit their booth after the online session and explore more business collaboration opportunities.
活动形式
我们会邀请投资人、产业方、创业者深度讨论各自对行业的见解以及对当下热点事件的解读。不但让你时刻紧跟行业热点，通过创新性的云展位更是让你可以与目标嘉宾开展更多的沟通与互动，创造更多商业合作的可能性，提供比线下对接更好的体验。
We will be inviting three keynote speakers as well as a panel discussion between entrepreneurs , investors and industry players to discuss their insights on the industry and their interpretation of current trending topics. Not only will you be able to be up to date with the industry’s latest trends, but through the company cloud booths, you will be able to communicate and interact with potential partners to create possibilities for a business cooperation.
活动安排
14:00 - 14:10 主办方介绍 Event Introduction
14:10 - 14: 25 中文/英文 CN/EN
钟靖 凯辉基金 投资副总裁 生命科学博士/MBA 百华协会会员
专注生物技术创新药，IVD诊断, 医疗器械等领域。从事分子诊断与RNA干扰研究多年，先后就职于美国Starting Gate Partners基金和华大基因、国科嘉和基金，并曾任迪康药业（600466）董事长助理，先后主导了微远医疗、迈景基因、菁良基因、微基因、南京智茂等投资，参与了华大智造、华大吉诺因等融资。
他拥有加州大学的细胞分子生物学博士和北卡大学的工商管理硕士学位，并任清华经管创业者加速器导师、 欧洲startupbootcamp孵化器导师。是美国病毒学会/遗传学会等获奖会员，深圳“梧桐凤凰”人才。
Gabriel Zhong，VP at Cathay Capital
PHD - University of California,Riverside
MBA - UNC Kenan-Flagler Business School
He is a a global healthcare investment professional with US educated Ph.D and top B-school MBA. Previously he worked for thinktank, pharma and medtech. He is now looking for healthcare investment opportunities with Cathay Capital. Member of the Bayhelix Group.
14:25 - 14:40 中文 CN
邹玉蓉，思创医惠投资管理部总经理
Zou Yurong， General Manager of SiChuangYiHui Investment Division
投资案例：杭州健海科技有限公司、南京岚煜生物科技有限公司、浙江亿联健医疗器械有限公司、领航基因科技（杭州）有限公司、杭州和正医药有限公司、嘉善加斯戴克医疗器械有限公司、浙江德尚韵兴图像科技有限公司等
14:40 - 14:55 中文 CN
王玉磊 技术发展总监 英特尔战略合作与创新业务部
主要负责AI+技术发展研究和推动人工智能, 机器人等创新生态对外技术合作。之前在英特尔半导体制造，软件开发项目运营管理，人工智能生态拓展等多个岗位任职，拥有十几年的丰富工作经验，对材料学，半导体制造工艺，开源软件，项目运营管理，AI+技术生态发展等领域有一定理解。
Wang Yulei, senior technical manager of Intel China Ecosystem Development Office. He mainly study the developing trend of AI, robotics and other cutting edge technologies and managing the technical engagement with AI+ ecosystem.
14:55 - 15:10 英文 EN
Rishi Tandon Head of Global BD, Holmusk
Holmusk是一家数据科学和健康技术公司，致力于为行为健康和慢性病的治疗提供客观证据作为核心工具。Holmusk入选世界经济论坛2019年度技术先锋榜单，并完成了2000万美金的A轮融资。
Founded in 2015, Holmusk is headquartered in Singapore with offices in North Carolina, New York City, London, Malaysia and Shanghai. Holmusk was recognized as a Technology Pioneer in 2019 by the World Economic Forum and is part of the Innovations in Healthcare’s 2020 Innovator Cohort.
15:10 - 15:30 中文
圆桌对话
- 2020年第一季度，医疗健康的融资数量下降剧烈，但是融资总额却与2019年同比却相差无几；还处于早期融资阶段的项目，应该如何规划自己的融资节奏？
- 如何看待医疗大健康细分领域的机会？2.AI+医疗，技术的变革，又会给初创企业带来什么样的机遇和变革？
- 创业项目如何寻找与产业对接合作的机会？
15:30 - 15:40 中文
互动问答
